RA
TEVA icon

Reby Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Reby Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$3K Buy
+302
New +$2.89K ﹤0.01% 537

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Reby Advisors's TEVA Position: Q4 2020 in Review

Reby Advisors opened a new position in Teva Pharmaceuticals (TEVA) in Q4 2020: 302 shares worth $3K. The stake represents ﹤0.01% of the portfolio and ranks #537 among its holdings.

449 funds tracked by Wall St. Rank hold TEVA as of Q4 2020.

  • Reby Advisors held 302 shares of Teva Pharmaceuticals worth $3K as of Q4 2020.
  • Teva Pharmaceuticals was a new Reby Advisors position in Q4 2020.
  • Teva Pharmaceuticals made up ﹤0.01% of Reby Advisors's portfolio in Q4 2020, its #537 holding.
  • 449 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2020.

Based on Reby Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.